SCHEMBL1360734

SCHEMBL1360734

CCOC(=O)c1coc2c(C(C)(C)C)cc(-c3ccc[nH]c3=O)cc12

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.40
KDM4E B2RXH2 5/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
CYP3A4 P08684 3/20 0.38
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CLEC4M Q9H2X3 1/20 0.35
MAPT P10636 2/20 0.34
LMNA P02545 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MAOA P21397 1/20 0.34
TSHR P16473 1/20 0.34
KMT2A Q03164 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRB2 P47870 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1360340 0.86 NAPRT (0.40) MAOBKDM4ECYP3A4MAPT
SCHEMBL1359292 0.85 CYP3A4 (0.38) CYP3A4MAPT
SCHEMBL1358066 0.84 MAOB (0.42) MAOBKDM4EALDH1A1CYP3A4L3MBTL1
SCHEMBL1358064 0.84 CYP3A4 (0.38) MAOBKDM4ECYP3A4MAOAKMT2A
SCHEMBL1358139 0.83 KMT2A (0.37) KDM4EALDH1A1HPGDNPSR1CYP3A4
SCHEMBL1359874 0.82 POLB (0.38) MAOBKDM4EHPGDCYP3A4NPC1
SCHEMBL1360055 0.81 CYP3A4 (0.37) KDM4EALDH1A1HPGDNPSR1CYP3A4
SCHEMBL1359878 0.81 ABL1 (0.41) MAOBCYP3A4RAB9AKMT2A
SCHEMBL1357867 0.81 CYP3A4 (0.36) KDM4EALDH1A1HPGDNPSR1CYP3A4
SCHEMBL1360132 0.81 CYP3A4 (0.35) CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067442-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2011-11-29 US disclosed
EP-2334662-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. Hoffmann-La Roche AG (CH) 2011-06-22 EP disclosed
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-04-01 US disclosed
WO-2010034671-A1 PYRINE OR PYRAZINE DERIVATIVES FOR TREATING HCV F. HOFFMANN-LA ROCHE AG (CH) 2010-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, POLR2A, HCCS MAOB 151/4885KDM4E 2198/4885ALDH1A1 1038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.